Part,  Chapter, Paragraph

 1    I,     2.  4    |        interventions and thrombolytic therapy). Apparently, while these
 2    I,     2. 10.  2|       discovery and drug delivery and therapy, for biomarker discovery,
 3   II,     5.  1.  2|        biomedicine and evidence-based therapy. Patient-centeredness is
 4   II,     5.  1.  3|          pharmacological and physical therapy .~ ~
 5   II,     5.  2.  3|              identifying thrombolytic therapy use from hospital in-patient
 6   II,     5.  3.  2|            practices in diagnosis and therapy so as to interpret these
 7   II,     5.  3.  7|            integrate these drugs into therapy programs. It is necessary
 8   II,     5.  4.  1|       necessitating renal replacement therapy: dialysis or transplantation);~
 9   II,     5.  4.  2|    transplantation (renal replacement therapy in patients with diabetes/
10   II,     5.  4.  2|    transplantation (renal replacement therapy) in patients with diabetes /
11   II,     5.  4.  2|    transplantation (renal replacement therapy) per 100,000 individuals
12   II,     5.  5.  3|          Despite improvements in drug therapy and in mental health services,
13   II,     5.  5.  3|       psychotherapy and psycho-social therapy. While nearly all people
14   II,     5.  5.  3|             and cognitive behavioural therapy. For other treatment approaches,
15   II,     5.  5.  3|          practice of focusing on drug therapy and neglecting psychosocial
16   II,     5.  5.  3|           further improvement of drug therapy;~· ensure the delivery of
17   II,     5.  5.  3|               and cognitive behaviour therapy. Psychol Med 32(5):763-82.~
18   II,     5.  5.  3|           Escalating Immunomodulatory Therapy of MS Consensus Paper~·
19   II,     5.  5.  3|                The multiple sclerosis therapy consensus group (MSTCG)
20   II,     5.  5.  3|         Sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG)
21   II,     5.  5.  3|             MSTCG (Multiple sclerosis therapy consensus group) and Rieckmann
22   II,     5.  5.  3|           Escalating immunomodulatory therapy of multiple sclerosis. Update.
23   II,     5.  5.  3|             MSTCG (Multiple sclerosis therapy consensus group) (2007): “
24   II,     5.  5.  3|           Escalating Immunomodulatory Therapy of MS Consensus Paper ,
25   II,     5.  5.  3|              MSTCG~Multiple Sclerosis Therapy Consensus Group~PML~Progressive
26   II,     5.  5.  3|               Research, Diagnosis and Therapy of Parkinson’s Disease -
27   II,     5.  5.  3|               1994): Epidemiology and therapy of Parkinson disease in
28   II,     5.  5.  3|             Brien PC (1993): Levodopa therapy and survival in idiopathic
29   II,     5.  6.Acr|               HRT~Hormone Replacement Therapy~NSAIDs~Non-steroidal anti-inflammatory
30   II,     5.  6.  3|               but hormone replacement therapy (HRT) is associated with
31   II,     5.  6.  3|             controlled on symptomatic therapy alone. Spontaneous remission
32   II,     5.  7.Acr|       Framework~RRT~Renal Replacement Therapy~WHO~World Health Organization~ ~
33   II,     5.  7.  1|             Data on renal replacement therapy (RRT) for ESRD in children
34   II,     5.  7.  1|      cost-effective renal replacement therapy (White et al, 2008). The
35   II,     5.  7.  1|  Classification Based on Severity and Therapy~ ~ ~Stage~Description~GFR*~(
36   II,     5.  7.  5|             Accessibility of dialysis therapy is possible in 92 dialysis
37   II,     5.  7.  7|          marker, and a new target for therapy. Kidney Int Suppl 2005 Sep;(
38   II,     5.  7.  7|        incidence of renal replacement therapy in developed countries come
39   II,     5.  7.  7|       Financing for renal replacement therapy in Italy: an evolving reality.
40   II,     5.  7.  7|        incidence of renal replacement therapy for end-stage renal disease
41   II,     5.  8.  1|              needing long term oxygen therapy and assisted ventilation,
42   II,     5.  9.  3|              prophylaxis, maintenance therapy etc.) for preventing heavier
43   II,     5.  9.  5|             the cost-benefit ratio of therapy and management measures,
44   II,     5.  9.  6|            impact the disease and its therapy as perceived by patients (
45   II,     5. 11.  4|           time lost for daily topical therapy and skin care in many skin
46   II,     5. 15.  4|               the Council on advanced therapy medicinal products (European
47   II,     5. 15.  4|              traceability of advanced therapy products.~ ~At Member State
48   II,     5. 15.  6|             November 2007 on advanced therapy medicinal products and amending
49   II,     6.  3.  3|         highly active anti-retroviral therapy (HAART). More work is needed
50   II,     6.  3.  3|         improve accessibility of this therapy to PLHIV. Counselling and
51   II,     6.  3.  4|         progression, while preventive therapy reduces this risk. The BCG
52   II,     7.  4.  6|              of cognitive behavioural therapy. Trends towards benefits
53   II,     7.  4.  6|          emergency cards, dialectical therapy and specific medicinal products.~ ~
54   II,     9        |              with hormone replacement therapy (Beral, 2003), and higher
55   II,     9.  3.  1|            involves androgen ablation therapy, has a marked effect on
56   II,     9.  3.  1|         changes requiring replacement therapy occur.~ ~While androgen
57   II,     9.  3.  1|               candidates for androgen therapy. Various guidelines have
58   II,     9.  3.  1|              with hormone replacement therapy (Beral, 2003), and higher
59   II,     9.  3.  1|               and hormone-replacement therapy in the Million Women Study.
60   II,     9.  3.  1|              ART~Androgen Replacement Therapy~BMD~Bone Mineral Density~
61   II,     9.  4.  3|            diagnostic investigations, therapy input and outpatient review (
62   II,     9.  5.  3|              with hormone replacement therapy (Beral, 2003), and higher
63   II,     9.  5.  6|               and hormone-replacement therapy in the Million Women Study.
64  III,    10.  2.  1|        pharmacotherapy and behavioral therapy. These are most effective
65  III,    10.  2.  1|        pharmacotherapy and behavioral therapy probably yields best results.~ ~
66  III,    10.  2.  1|                  Nicotine replacement therapy (NRT) in the form of patches,
67  III,    10.  2.  1|             integration of behavioral therapy can increase the quitting
68  III,    10.  2.  4|          approaches to prevention and therapy (Khoury, 1996; Brand, 2002;
69  III,    10.  2.  4|             individual prevention and therapy develop the more the use
70  III,    10.  4.  2| antimicrobials commonly used in human therapy. This is especially the
71  III,    10.  6.  2|        interventions and thrombolytic therapy). Apparently, while these
72   IV,    11.  3.  2|              Community level by ATC-1 therapy area (2004-2010)~ ~The expected
73   IV,    11.  5.  5|           demand of organ replacement therapy by increasing donation rates.~-
74   IV,    12.  2    |        pharmacotherapy and behavioral therapy. Only 3% of smokers manage
75   IV,    12.  2    |        pharmacotherapy and behavioral therapy probably yields best results.
76   IV,    12.  2    |         results. Nicotine replacement therapy (NRT) in form of patches,
77   IV,    12.  2    |             integration of behavioral therapy can increase the quitting
78   IV,    12. 10    |             Detoxification, long term therapy and rehabilitative measures
79   IV,    12. 10    |             on primary prevention and therapy of eating disorders (see www. – “
80   IV,    12. 10    |              epizootic diseases. Gene therapy as well is closely controlled:
81   IV,    12. 10    |            Committee for Somatic Gene Therapy of the German Medical Association (
82   IV,    12. 10    |          Hypertension Diagnostics and Therapy /Croatian edition/~Interactions